Kohjin Bio Toekomstige groei
Future criteriumcontroles 3/6
Kohjin Bio is forecast to grow earnings and revenue by 25.7% and 3.7% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be 12% in 3 years.
Belangrijke informatie
25.7%
Groei van de winst
17.8%
Groei van de winst per aandeel
| Biotechs winstgroei | 10.7% |
| Inkomstengroei | 3.7% |
| Toekomstig rendement op eigen vermogen | 12.0% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 28 May 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2026 | 5,130 | 671 | -189 | 980 | 1 |
| 3/31/2025 | 4,717 | 618 | -254 | 482 | 1 |
| 3/31/2024 | 4,770 | 384 | 261 | 823 | N/A |
| 3/31/2023 | 4,742 | 829 | N/A | N/A | N/A |
| 3/31/2022 | 3,947 | 587 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 177A's forecast earnings growth (25.7% per year) is above the savings rate (0.3%).
Winst versus markt: 177A's earnings (25.7% per year) are forecast to grow faster than the JP market (8.9% per year).
Hoge groeiwinsten: 177A's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 177A's revenue (3.7% per year) is forecast to grow slower than the JP market (4.2% per year).
Hoge groei-inkomsten: 177A's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 177A's Return on Equity is forecast to be low in 3 years time (12%).